FDA lifts hold on Legend Biotech's follow-up CAR-T targeting CD4+
Legend Biotech got some good news last week that it divulged during its first quarter report Wednesday.
Discussing its earnings with investors early this morning, Legend revealed that the FDA had lifted a clinical hold on May 25 from its Phase I CAR-T therapy targeting malignant CD4+ T cells. Regulators lifted the hold on the program known as LB1901 after it spent about three and a half months on the shelf.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.